Transmission of viral disease to the recipient through the donor liver

Current Opinion in Organ Transplantation

Volumn 12, Issue 3, 2007, Pages 231-241

  Bonatti, Hugo ^a   Sawyer, Robert ^a   Dickson, Rolland C ^b   Razonable, Raymond ^c   Schmitt, Timothy ^a   Mendez, Julio ^b   Singh, Nina ^d   Pruett, Timothy ^a,e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cytomegalovirus; Epstein Barr virus; Extended criteria donor; Liver transplant; Prophylaxis; Viral disease

Indexed keywords

HEPATITIS B ANTIBODY; LAMIVUDINE;

CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; GRAFT RECIPIENT; HERPES SIMPLEX VIRUS; HERPES VIRUS; HUMAN; INFECTION PREVENTION; LIVER GRAFT; LIVER TRANSPLANTATION; MORTALITY; ORGAN DONOR; REVIEW; SEROPREVALENCE; VIRUS INFECTION; VIRUS TRANSMISSION;

EID: 34249078882     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32814e6b67     Document Type: Review

References (138)

1. Brown KA. Liver transplantation. Curr Opin Gastroenterol 2005; 21:331-336.
2. Hirose R, Vincenti F. Immunosuppression: today, tomorrow, and withdrawal. Semin Liver Dis 2006; 26:201-210.
3. Said A, Lucey MR. Liver transplantation: an update. Curr Opin Gastroenterol 2006; 22:272-278.
4. Foxton MR, Kendrick S, Sizer E, et al. Change in model for end-stage liver disease score on the transplant waiting list predicts survival in patients undergoing liver transplantation. Transpl Int 2006; 19:988-994.
5. Cameron AM, Ghobrial RM, Yersiz H, et al. Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants. Ann Surg 2006; 243:748-753. This article reviews the experience with an extensive number of ECDs from a single center.
6. Lopez-Navidad A, Caballero F. Extended criteria for organ acceptance: strategies for achieving organ safety and for increasing organ pool. Clin Transplant 2003; 17:308-324.
7. Pungpapong S, Krishna M, Abraham SC, et al. Clinicopathologic findings and outcomes of liver transplantation using grafts from donors with unrecognized and unusual diseases. Liver Transpl 2006; 12:310-315.
8. Burton JR, Shaw-Stiffel TA. Use of hepatitis B core antibody-positive donors in recipients without evidence of hepatitis B infection: a survey of current practice in the United States. Liver Transpl 2003; 9:837-842.
9. Eastlund T. Infectious disease transmission through cell, tissue, and organ transplantation: reducing the risk through donor selection. Cell Transplant 1995; 4:455-477.
10. Nery JR, Nery-Avila C, Reddy KR. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation 2003; 75: 1179-1186.
11. Hellinger WC, Bonatti H, Machicao VI, et al. Effect of antiviral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liver transplantation. Mayo Clin Proc 2006; 81:1029-1033. In this article it is shown that ganciclovir prophylaxis is able to abrogate some of the secondary effects of cytomegalovirus.
12. Singh N, Dummer JS, Kusne S, et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158:124-131.
13. Razonable RR, Rivero A, Brown RA, et al. Detection of simultaneous beta-herpesvirus infections in clinical syndromes due to defined cytomegalovirus infection. Clin Transplant 2003; 17:114-120.
14. Fabrega E, Garcia-Suarez C, Guerra A. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach. Liver Transplantation 2003; 9:916-920.
15. Srinivasan A, Burton EC, Kuehnert MJ, et al., Rabies in Transplant Recipients Investigation Team. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med 2005; 352:1103-1111.
16. Iwamoto M, Jernigan DB, Guasch A, et al., West Nile Virus in Transplant Recipients Investigation Team. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003; 348:2196-2203.
17. Dickson RC, Everhart JE, Lake JR. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitic B core antigen. Gastroenterology 1997; 133:1668-1674.
18. Fischer SA, Graham MB, Kuehnert MJ, et al., LCMV in Transplant Recipients Investigation Team. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006; 354:2235-2249. This is a key article concerning transmission of lymphocytic choriomeningitis virus with human allografts.
19. Lautenschlager I, Halme L, Hockerstedt K, et al. Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations. Transpl Infect Dis 2006; 8:21-30. This is an update of the role of cytomegalovirus in liver transplantation.
20. Staras SA, Dollard SC, Radford KW, et al. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006; 43:1143-1151.
21. Razonable RR, Brown RA, Humar A, et al., PV16000 Study Group. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005; 192:1331-1339.
22. Kusne S, Smilack J. Transmission of rabies virus from an organ donor to four transplant recipients. Liver Transpl 2005; 11:1295-1297.
23. Kiberd BA, Forward K. Screening for West Nile virus in organ transplantation: a medical decision analysis. Am J Transplant 2004; 4:1296-1301.
24. Dietzschold B, Koprowski H. Rabies transmission from organ transplants in the USA. Lancet 2004; 364:648-649.
25. Kulkarni S, Cronin DC 2nd. Ethics in liver transplantation. Semin Liver Dis 2006; 26:234-238.
26. Pruett TL, Tibell A, Alabdulkareem A, et al. The ethics statement of the Vancouver Forum on the live lung, liver, pancreas, and intestine donor. Transplantation 2006; 81:1386-1387.
27. Delmonico FL. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 2000; 31:781-786.
28. Heo JS, Park JW, Lee KW, et al. Posttransplantation lymphoproliferative disorder in pediatric liver transplantation. Transplant Proc 2004; 36:2307-2308.
29. Holt D, Thomas R, Van Thiel D. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002; 137:572-576.
30. Manzelli A, Fisichella PM, Bonfrate G, Gaspari AL. When living related organ donation does not entail a healthy organ: moral implications for both the donor and the recipient. Arch Surg 2004; 139:1259.
31. Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl 2003; 9:451-462.
32. Fan J, Meng XQ, Yang MF, et al. Association of cytomegalovirus infection with human leukocyte antigen genotypes in recipients after allogeneic liver transplantation. Hepatobiliary Pancreat Dis Int 2006; 5:34-38. This paper gives insight into the complex interaction between cytomegalovirus and host immune system with regard to HLA types.
33. Ng IO, Chan KL, Shek WH, et al. High frequency of chimerism in transplanted livers. Hepatology 2003; 38:989-998.
34. Manez R, White LT, Linden P, et al. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation 1993; 55:1067-1071.
35. + T cells restricted by donor HLA alleles following liver transplantation. Liver Transpl 2005; 11:848-850.
36. Hove WR, van Hoek B, Bajema IM, et al. Extensive chimerism in liver transplants: vascular endothelium, bile duct epithelium, and hepatocytes. Liver Transpl 2003; 9:552-556.
37. Kozireva S, Nemceva G, Danilane I, et al. Prevalence of blood-borne viral infections (cytomegalovirus, human herpesvirus-6, human herpesvirus-7, human herpesvirus-8, human T-cell lymphotropic virus-I/II, human retrovirus-5) among blood donors in Latvia. Ann Hematol 2001; 80:669-673.
38. Kangro HO, Osman HK, Lau YL, et al. Seroprevalence of antibodies to human herpesviruses in England and Hong Kong. J Med Virol 1994; 43:91-96.
39. Washington K. Update on postliver transplantation infections, malignancies, and surgical complications. Adv Anat Pathol 2005; 12:221-226.
40. Petrova M, Muhtarova M, Nikolova M, et al. Chronic Epstein-Barr virus-related hepatitis in immunocompetent patients. World J Gastroenterol 2006; 12: 5711-5716.
41. Ichai P, Afonso AM, Sebagh M, et al. Herpes simplex virus-associated acute liver failure: a difficult diagnosis with a poor prognosis. Liver Transpl 2005; 11:1550-1555.
42. Natoli S, Ciotti M, Paba P, et al. A novel mutation of varicella-zoster virus associated to fatal hepatitis. J Clin Virol 2006; 37:72-74.
43. Mendel I, de Matteis M, Bertin C, et al. Fulminant hepatitis in neonates with human herpesvirus 6 infection. Pediatr Infect Dis J 1995; 14:993-997.
44. Tajiri H, Tanaka-Taya K, Ozaki Y, et al. Chronic hepatitis in an infant, in association with human herpesvirus-6 infection. J Pediatr 1997; 131:473-475.
45. Hashida T, Komura E, Yoshida M, et al. Hepatitis in association with human herpesvirus-7 infection. Pediatrics 1995; 96 (4 Pt 1):783-785.
46. Mandell GL, Bennett JE, Raphael Dolin R, Principles and practice of infectious diseases. 6th ed. Part III, section A. Orlando, Florida: WB Saunders; 2006. pp. 131-137.
47. Seehofer D, Rayes N, Neumann UP, et al. Changing impact of cytomegalovirus in liver transplantation: a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis. Transpl Int 2005; 18:941-948.
48. Razonable RR, Brown RA, Humar A, et al., PV16000 Study Group. Herpesvirus infections in solid organ transplant patients at high risk of primary cytomegalovirus disease. J Infect Dis 2005; 192:1331-1339.
49. Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 2003; 10:60-65.
50. Singh N, Wannstedt C, Keyes L, et al. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl 2005; 11:700-704.
51. Woodman CB, Collins SI, Vavrusova N, et al. Role of sexual behavior in the acquisition of asymptomatic Epstein-Barr virus infection: a longitudinal study. Pediatr Infect Dis J 2005; 24:498-502.
52. Adams LA, Deboer B, Jeffrey G, et al. Ganciclovir and the treatment of Epstein-Barr virus hepatitis. J Gastroenterol Hepatol 2006; 21:1758-1760.
53. Ader F, Chatellier D, Le Berre R, et al. Fulminant Epstein-Barr virus (EBV) hepatitis in a young immunocompetent subject. Med Mal Infect 2006; 36:396-398.
54. Mendez-Sanchez N, Aguilar-Dominguez C, Chavez-Tapia NC, Uribe M. Hepatic manifestations of Epstein-Barr viral infection. Ann Hepatol 2005; 4:205-209.
55. Li C, Chen RS, Hung SK, et al. Detection of Epstein-Barr virus infection and gene expression in human tumors by microarray analysis. J Virol Methods 2006; 133:158-166.
56. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2005; 23:7574-7582.
57. Allen UD, Farkas G, Hebert D, et al. Risk factors for posttransplant lymphoproliferative disorder in pediatric patients: a case-control study. Pediatr Transplant 2005; 9:450-455.
58. Nuckols JD, Baron PW, Stenzel TT, et al. The pathology of liver-localized posttransplant lymphoproliferative disease: a report of three cases and a review of the literature. Am J Surg Pathol 2000; 24:733-741.
59. Guthery SL, Heubi JE, Bucuvalas JC, et al. Determination of risk factors for Epstein-Barr virus-associated post transplant lymphoproliferative disorder in paediatric liver transplant recipients using objective case ascertainment. Transplantation 2003; 75:987-993.
60. Miyagawa H, Yamanishi K. The epidemiology and pathogenesis of infections caused by the high numbered human herpesviruses in children: HHV-6, HHV-7 and HHV-8. Curr Opin Infect Dis 1999; 12:251-255.
61. Yoshikawa T. Human herpesvirus 6 causes hepatitis in transplant recipients. Intern Med 2006; 45:417-418. Yoshikawa demonstrates that HHV 6 causes hepatitis in organ recipients.
62. Harma M, Hockerstedt K, Lyytikainen O, Lautenschlager I. HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation. J Med Virol 2006; 78:800-805.
63. Razonable RR, Paya CV. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl 2002; 8:651-658.
64. Mendez JC, Dockrell DH, Espy MJ, et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001; 183:179-184.
65. DesJardin JA, Cho E, Supran S, et al. Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients. Clin Infect Dis 2001; 33:1358-1362.
66. Singh N, Husain S, Carrigan DR, et al. Impact of human herpesvirus-6 on the frequency and severity of recurrent hepatitis C virus hepatitis in liver transplant recipients. Clin Transplant 2002; 16:92-96.
67. Cesarman E, Mesri EA. Kaposi sarcoma-associated herpesvirus and other viruses in human lymphomagenesis. Curr Top Microbiol Immunol 2007; 312: 263-287.
68. Marcelin AG, Calvez V, Dussaix E. KSHV after an organ transplant: should we screen? Curr Top Microbiol Immunol 2007; 312:245-262. This article suggests that screening for HHV8 may be of benefit in selected donor and recipient populations.
69. Martro E, Bulterys M, Stewart JA, et al. Comparison of human herpesvirus 8 and Epstein-Barr virus seropositivity among children in areas endemic and nonendemic for Kaposi's sarcoma. J Med Virol 2004; 72:126-131.
70. Marcelin AG, Roque-Afonso AM, Hurtova M, et al. Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transpl 2004; 10:295-300.
71. Boeckle E, Boesmueller C, Wiesmayr S, et al. Kaposi sarcoma in solid organ transplant recipients: a single center report. Transplant Proc 2005; 37: 1905-1909.
72. Mirza D, Hastings M, Reyes J, et al. Organ donation from children with meningitis. Pediatr Infect Dis J 2003; 22:475.
73. Kleinschmidt-DeMasters BK, Gilden DH. The expanding spectrum of herpesvirus infections of the nervous system. Brain Pathol 2001; 11:440-451.
74. Duckro AN, Sha BE, Jakate S, et al. Herpes simplex virus hepatitis: expanding the spectrum of disease. Transpl Infect Dis 2006; 8:171-176.
75. Velasco M, Llamas E, Guijarro-Rojas M, Ruiz-Yague M. Fulminant herpes hepatitis in a healthy adult: a treatable disorder? J Clin Gastroenterol 1999; 28:386-389.
76. Lechiche C, Le Moing V, Francois Perrigault P, Reynes J. Fulminant varicella hepatitis in a human immunodeficiency virus infected patient: case report and review of the literature. Scand J Infect Dis 2006; 38:929-931.
77. Longerich T, Eisenbach C, Penzel R, et al. Recurrent herpes simplex virus hepatitis after liver retransplantation despite acyclovir therapy. Liver Transpl 2005; 11:1289-1294.
78. Kusne S, Pappo O, Manez R, et al. Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients. Transplantation 1995; 60:619-621.
79. Alonso EM, Fox AS, Franklin WA, Whitington PF. Postnecrotic cirrhosis following varicella hepatitis in a liver transplant patient. Transplantation 1990; 49:650-653.
80. Cakaloglu Y, Devlin J, O'Grady J, et al. Importance of concomitant viral infection during late acute liver allograft rejection. Transplantation 1995; 59:40-45.
81. Saab S, Chang AJ, Comulada S, et al. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl 2003; 9:1053-1061.
82. - organ donors. Transplantation 1995; 59:230-234.
83. Roche B, Samuel D, Gigou M. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26:517-526.
84. Yen RD, Bonatti H, Mendez J, et al. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006; 6 (5 Pt 1):1077-1083. Selection of lamivudin resistant HBV may develop several years following liver transplantation, transmitted through a liver allograft.
85. Dodson SF, Issa S, Araya V. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Clin Transplant 1997; 64:1582-1584.
86. Douglas DD, Rakela J, Wright TL. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 3:105-111.
87. Uemoto S, Sugiyama K, Marusawa H. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Clin Transplant 1998; 65:494-499.
88. Prieto M, Gomez MD, Berenguer M. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001; 7:51-58.
89. Roque-Afonso AM, Feray C, Samuel D. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut 2002; 50:95-99.
90. Manzarbeitia C, Reich DJ, Ortiz JA. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl 2002; 8:556-561.
91. Chen YS, Wang CC, deVilla VH. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002; 16:405-409; HBV.
92. Ricchiuti A, Brunati A, Mirabella S, et al. Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience. Transplant Proc 2005; 37:2569-2570.
93. Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCV+ allografts. Liver Transpl 2006; 12:1496-1503. Similar to HCV-negative organs, recurrence of HCV following liver transplantation is highly dependent on the donor age in HCV-positive organs.
94. Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002; 73:582-587.
95. Saab S, Ghobrial RM, Ibrahim AB, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant 2003; 3:1167-1172.
96. Tugwell BD, Patel PR, Williams IT, et al. Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med 2005; 143:648-654.
97. Jain A, Orloff M, Abt P, et al. Use of hepatitis B core antibody-positive liver allograft in hepatitis C virus-positive and -negative recipients with use of short course of hepatitis B immunoglobulin and lamivudine. Transplant Proc 2005; 37:3187-3189.
98. Prakoso E, Strasser SI, Koorey DJ, et al. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibodypositive donors. Clin Transplant 2006; 20:369-373.
99. Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibodypositive donors in orthotopic liver transplantation. Arch Surg 2002; 137:572-575.
100. Simonds RJ. HIV transmission by organ and tissue transplantation. AIDS 1993; 7 (Suppl 2):S35-S38.
101. Zarranz Imirizaldu JJ, Gomez Esteban JC, Rouco Axpe I, et al. Posttransplantation HTLV-1 myelopathy in three recipients from a single donor. J Neurol Neurosurg Psychiatry 2003; 74:1080-1084.
102. Gonzalez-Perez MP, Munoz-Juarez L, Cardenas FC, et al. Human T-cell leukemia virus type I infection in various recipients of transplants from the same donor. Transplantation 2003; 75:1006-1011.
103. Granwehr BP, Lillibridge KM, Higgs S, et al. West Nile virus; where are we now? Lancet 2004; 4:547-556.
104. OPTN. Organ Procurement and Transplantation Network. http://www.optn.org/ news/newsDetail.asp?id=303. [Accessed 7 November 2006]
105. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 2006; S57 (Suppl 4):561.
106. Mackenzie JW, Westaway EG. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol 2001; 75:10787-10799.
107. Wu SR, Lee CJ, Liao CL, et al. Antiviral effects of an iminosugar derivative on flavivirus infection. J Virol 2002; 76:3596-3604.
108. Burton EC, Burns DK, Opatowsky MJ, et al. Rabies encephalomyelitis: clinical, neuroradiological, and pathological findings in 4 transplant recipients. Neurology 2006; 62:873-882.
109. Hellenbrand W, Meyer C, Rasch G, et al. Cases of rabies in Germany following organ transplantation. Euro Surveillance 2006; 10:E050224-E060226.
110. Misak A. Rabies after solid organ transplantation. Can Med Assoc J 2004; 171:327.
111. Paddock C, Ksiazek T, Comer JA, et al. Pathology of fatal lymphocytic choriomeningitis virus infection in multiple organ transplant recipients from a common donor. Mod Pathol 2005; 18 (Suppl):263A-264A.
112. Centers for Disease Control and Prevention. Lymphocytic choriomeningitis virus infection in organ transplant recipients: Massachusetts, Rhode Island, 2005. MMWR Morb Mortal Wkly Rep 2005; 54:537-539.
113. Rao YG, Mirza DF. Infections transmitted from donors to recipients following organ transplantation. Natl Med J India 2005; 18:189-194.
114. Markin RS, Langnas AN, Donovan JP, et al. Opportunistic viral hepatitis in liver transplant recipients. Transplant Proc 1991; 23 (1 Pt 2):1520-1521.
115. Saad RS, Demetris AJ, Lee RG, et al. Adenovirus hepatitis in the adult allograft liver. Transplantation 1997; 64:1483-1485.
116. Brundler MA, Rodriguez-Baez N, Jaffe R, et al. Adenovirus ascending cholangiohepatitis. Pediatr Dev Pathol 2003; 6:156-159.
117. Cames B, Rahier J, Burtomboy G, et al. Acute adenovirus hepatitis in liver transplant recipients. J Pediatr 1992; 120:33-37.
118. Koneru B, Atchison R, Jaffe R, et al. Serological studies of adenoviral hepatitis following pediatric liver transplantation. Transplant Proc 1990; 22:1547-1548.
119. Varki NM, Bhuta S, Drake T, Porter DD. Adenovirus hepatitis in two successive liver transplants in a child. Arch Pathol Lab Med 1990; 114:106-109; Links.
120. Carter BA, Karpen SJ, Quiros-Tejeira RE, et al. Intravenous cidofovir therapy for disseminated adenovirus in a pediatric liver transplant recipient. Transplantation 2002; 74:1050-1052.
121. Arav-Boger R, Echavarria M, Forman M, et al. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. Pediatr Infect Dis J 2000; 19:1097-1100.
122. Genovese D, Dettori S, Argentini C, et al. Molecular characterisation of SENV and TTV infections in hepatopathic liver-transplant patients: brief report. Arch Virol 2004; 149:1423-1433.
123. Alter HJ. Transfusion transmitted hepatitis C and non-A, non-B, non-C. Vox Sang 1994; 67 (Suppl 3):19-24.
124. Lee WM, Brown KE, Young NS, et al., Acute Liver Failure Study Group (ALFSG). Brief report: no evidence for parvovirus B19 or hepatitis E virus as a cause of acute liver failure. Dig Dis Sci 2006; 51:1712-1715.
125. Karetnyi YV, Beck PR, Markin RS, et al. Human parvovirus B19 infection in acute fulminant liver failure. Arch Virol 1999; 144:1713-1724.
126. Jonetzko P, Graziadei I, Nachbaur K, et al. Fatal course of parvovirus B19-associated myocarditis in a female liver transplant recipient. Liver Transpl 2005; 11:463-466.
127. Sainokami S, Abe K, Kumagai I, et al. Epidemiological and clinical study of sporadic acute hepatitis E caused by indigenous strains of hepatitis E virus in Japan compared with acute hepatitis A. J Gastroenterol 2004; 39:702-703.
128. Rochling FA, Jones WF, Chau K, et al. Acute sporadic non-A, non-B, non-C, non-D, non-D, non-E hepatitis. Hepatology 1997; 25:478-483.
129. Alter HJ, Nakatsuji Y, Melpolder J, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997; 336:747-754.
130. Lunel F, Frangeul L, Chuteau C, et al. Transfusion-associated or nosocomial hepatitis G virus infection in patients undergoing surgery. Transfusion 1998; 38:1097-1103.
131. Gottesdiener KM. Transplanted infections: donor-to-host transmission with the allograft. Ann Intern Med 1989; 110:1001-1016.
132. Bonatti H, Machicao V, Dickson RC, Mendez J. Results of liver transplantation in HBV core antibody positive individuals and recipients of allografts from HBV core antibody positive individuals. Eur Surg 2005; 37:15.
133. Kauffman HM, Taranto SE. Human T-cell lymphotrophic virus type-1 and organ donors. Transplantation 2003; 76:745-746.
134. Green M, Michaels MG, Katz BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6:1906-1912.
135. Humar A, Hebert D, Davies HD, et al. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder. Transplantation 2006; 81:856-861.
136. Pescovitz MD. Benefits of cytomegalovirus prophylaxis in solid organ transplantation. Transplantation 2006; 82 (2 Suppl):S4-S8.
137. Loss GE, Mason AL, Nair S. Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors? Liver Transpl 2003; 9:1258-1264.
138. Horlander JC, Boyle N, Manam R. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci 1999; 318:304-307.